CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
The CCTG Patient Representative Committee (PRC) sends a heartfelt thank you to two key members who will be leaving us this month, Marie-Térèse Little and Carol Gordon. Their contributions have been transformative, and we are fortunate to have had their unwavering engagement and insight over the years. Their dedication will continue to inspire and elevate the work of the committee to improve cancer research for patients everywhere.
The CCTG Annual Spring Meeting is only 5 weeks away! If you have not registered or requested an Invitation, please do so now! Here are some things for you to keep in mind:
Meeting Information
All meeting information is available on the Spring Meeting Web Page and includes:
A new national initiative as been funded by the Canadian Cancer Society, through their Breakthrough Team Grant competition. The Canadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT), is bringing together researchers, clinicians, policymakers, and people living with advanced cancer to explore the potential of psychedelic-assisted therapy as a transformative approach to cancer care.
Primary Publication
CCTG will be holding the next CRA Lunch and Learn on Wednesday March 26th, 2025, at 12 pm ET. Session 4 will cover the topic of Introduction to RIPPLE: CCTG's rostering and participants list system
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Gastro-Intestinal Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Gastro-Intestinal Disease Site Committee, the Gastro-Intestinal Disease Site Executive Committee, and the CCTG Patient Representative Committee.